Exelon Corporation Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? Exelon Corporation Common Stock trades at $41.74 (market cap $42.99B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Exelon Corporation Common Stock is far larger — about 20.1× Recursion Pharmaceuticals Inc's market cap, and Exelon Corporation Common Stock pays a 4.03% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EXC | RXRX | |
|---|---|---|
Market Cap | $42.99B | $2.14B |
Volume | 7,570,408 | 30,789,535 |
Sector | Utilities | Health |
52-Week High | $50.29 | $6.79 |
52-Week Low | $40.20 | $2.84 |
Enterprise Value | $93.85B | $1.66B |
Dividend Yield | 4.03% | — |
Typical Hold Time | — | 22 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →